Commercial PA Criteria

Effective: May 4, 2016

Prior Authorization: Veltassa

Products Affected: Veltassa (patiromer) powder for oral suspension

Medication Description:
Veltassa is a cation exchange polymer FDA approved for the treatment of hyperkalemia as characterized by high serum potassium levels. Veltassa is not indicated for the emergency treatment of life-threatening hyperkalemia because of its delayed-onset of action. Veltassa is a non-absorbed, cation exchange polymer that contains calcium-sorbitol counterion. Veltassa increases fecal potassium excretion through binding of potassium in the lumen of the distal colon, resulting in reduction of serum potassium levels.

Covered Uses: Hyperkalemia

Exclusion Criteria:

1. Emergency treatment of life-threatening hyperkalemia

Required Medical Information:

1. Diagnosis
2. Previous therapies tried/failed
3. Medical history

Age Restrictions: 18 years of age and older.

Prescriber Restrictions: N/A

Coverage Duration: 12 months

Other Criteria:

A. Patient has a diagnosis of non-life threatening hyperkalemia; **AND**
B. Patient follows a low potassium diet (less than or equal to 3 grams per day); **AND**
C. Patient has tried dosage adjustments or discontinuation of medications known to cause hyperkalemia (e.g., angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker, aldosterone antagonist, nonsteroidal anti-inflammatory drugs [NSAIDs]); **AND**
D. Patient has had an inadequate treatment response, intolerance, or contraindication to a loop or thiazide diuretic; **AND**
E. Patient has had an inadequate response, intolerance or contraindication to sodium polystrene sulfonate at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced.

References:

1. Veltassa (patiromer) [prescribing information]. Redwood City, CA: Vifor Pharma Inc; October 2023.
2. Pantiromer. Lexicomp Online [Internet database], Hudson, Ohio: Wolters Kluwer Health, Inc; March 2016.

Policy Revision history

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	New Policy	New Policy	All	3/22/2016
2	Update	Updated clinical criteria to industry standards – addition of previous diuretic use	Required Medical Information Other Criteria	12/27/2019
3	Update	Updated products affected from Veltassa suspension to Veltassa (patiromer) powder for oral suspension	Products Affected	3/11/2025